{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:42:58Z","timestamp":1787064178943,"version":"build-2736575974"},"reference-count":58,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T00:00:00Z","timestamp":1726099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-alcoholic fatty acid disease (NAFLD) is caused by a build-up of fat in the liver, inducing local inflammation and fibrosis. We evaluated the effects of probiotic lactic acid-generating bacteria (LAB) derived from a traditional fermented beverage in a mouse model of NAFLD. The LAB isolated from this traditional Korean beverage were screened using the human hepatic cell line HepG2, and Lactocaseibacillus paracasei HY7207 (HY7207), which was the most effective inhibitor of fat accumulation, was selected for further study. HY7207 showed stable productivity in industrial-scale culture. Whole-genome sequencing of HY7207 revealed that the genome was 2.88 Mbp long, with 46.43% GC contents and 2778 predicted protein-coding DNA sequences (CDSs). HY7207 reduced the expression of lipogenesis and hepatic apoptosis-related genes in HepG2 cells treated with palmitic acid. Furthermore, the administration of 109 CFU\/kg\/day of HY7207 for 8 weeks to mice fed an NAFLD-inducing diet improved their physiologic and serum biochemical parameters and ameliorated their hepatic steatosis. In addition, HY7207 reduced the hepatic expression of genes important for lipogenesis (Srebp1c, Fasn, C\/ebpa, Pparg, and Acaca), inflammation (Tnf, Il1b, and Ccl2), and fibrosis (Col1a1, Tgfb1, and Timp1). Finally, HY7207 affected the expression of the apoptosis-related genes Bax (encoding Bcl2 associated X, an apoptosis regulator) and Bcl2 (encoding B-cell lymphoma protein 2) in the liver. These data suggest that HY7207 consumption ameliorates NAFLD in mice through effects on liver steatosis, inflammation, fibrosis, and hepatic apoptosis. Thus, L. paracasei HY7207 may be suitable for use as a functional food supplement for patients with NAFLD.<\/jats:p>","DOI":"10.3390\/ijms25189870","type":"journal-article","created":{"date-parts":[[2024,9,12]],"date-time":"2024-09-12T10:15:27Z","timestamp":1726136127000},"page":"9870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Lacticaseibacillus paracsei HY7207 Alleviates Hepatic Steatosis, Inflammation, and Liver Fibrosis in Mice with Non-Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6923-6113","authenticated-orcid":false,"given":"Hyeon-Ji","family":"Kim","sequence":"first","affiliation":[{"name":"R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye-Jin","family":"Jeon","sequence":"additional","affiliation":[{"name":"R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Gun","family":"Kim","sequence":"additional","affiliation":[{"name":"R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-2871","authenticated-orcid":false,"given":"Joo-Yun","family":"Kim","sequence":"additional","affiliation":[{"name":"R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Jung","family":"Shim","sequence":"additional","affiliation":[{"name":"R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Lee","sequence":"additional","affiliation":[{"name":"R&BD Center, hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-alcoholic fatty liver disease: The diagnosis and management","volume":"7","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S1665-2681(19)31246-3","article-title":"Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients","volume":"13","author":"Buss","year":"2014","journal-title":"Ann. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15518","DOI":"10.3748\/wjg.v20.i42.15518","article-title":"Gut-liver axis and probiotics: Their role in non-alcoholic fatty liver disease","volume":"20","author":"Paolella","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000282080","article-title":"Epidemiology of non-alcoholic fatty liver disease","volume":"28","author":"Bellentani","year":"2010","journal-title":"Dig. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1365-2036.2011.04724.x","article-title":"Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults","volume":"34","author":"Vernon","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yin, X., Guo, X., Liu, Z., and Wang, J. (2023). Advances in the diagnosis and treatment of non-alcoholic fatty liver disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032844"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","article-title":"Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease","volume":"75","author":"Ipsen","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Li, N., Li, X., Ding, Y., Liu, X., Diggle, K., Kisseleva, T., and Brenner, D.A. (2023). SREBP regulation of lipid metabolism in liver disease, and therapeutic strategies. Biomedicines, 11.","DOI":"10.20944\/preprints202310.2022.v1"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.4254\/wjh.v7.i8.1012","article-title":"Peroxisome proliferator-activated receptors as targets to treat non-alcoholic fatty liver disease","volume":"7","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1074\/jbc.M113.541110","article-title":"Sterol regulatory element-binding protein-1 (SREBP-1) is required to regulate glycogen synthesis and gluconeogenic gene expression in mouse liver","volume":"289","author":"Ruiz","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-0041-1731709","article-title":"Role of lipogenesis rewiring in hepatocellular carcinoma","volume":"Volume 42","author":"Zhou","year":"2022","journal-title":"Seminars in Liver Disease"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0032-1306423","article-title":"Dyslipidemia in patients with nonalcoholic fatty liver disease","volume":"Volume 32","author":"Chatrath","year":"2012","journal-title":"Seminars in Liver Disease"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s11883-022-01028-4","article-title":"Management of dyslipidemia in patients with non-alcoholic fatty liver disease","volume":"24","author":"Martin","year":"2022","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/egh.11.6","article-title":"Apoptosis in nonalcoholic fatty liver disease: Diagnostic and therapeutic implications","volume":"5","author":"Alkhouri","year":"2011","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2023.10.025","article-title":"CD1d protects against hepatocyte apoptosis in non-alcoholic steatohepatitis","volume":"80","author":"Lei","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3350\/kjhep.2011.17.3.247","article-title":"Apoptosis and diagnosis of nonalcoholic steatohepatitis","volume":"17","author":"Kim","year":"2011","journal-title":"Korean J. Hepatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.3748\/wjg.v24.i25.2661","article-title":"Apoptosis and non-alcoholic fatty liver diseases","volume":"24","author":"Kanda","year":"2018","journal-title":"World J. Gastroenterol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"727","DOI":"10.3748\/wjg.v18.i8.727","article-title":"Role of cytokines and chemokines in non-alcoholic fatty liver disease","volume":"18","author":"Braunersreuther","year":"2012","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Nagata, N., Chen, G., Xu, L., and Ando, H. (2022). An update on the chemokine system in the development of NAFLD. Medicina, 58.","DOI":"10.20944\/preprints202205.0252.v1"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-\u03b2 in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1600240","DOI":"10.1002\/mnfr.201600240","article-title":"Probiotics, gut microbiota, and their influence on host health and disease","volume":"61","author":"Delgado","year":"2017","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1756283X12459294","article-title":"Effects of probiotics on gut microbiota: Mechanisms of intestinal immunomodulation and neuromodulation","volume":"6","author":"Hemarajata","year":"2013","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.4014\/jmb.1906.06064","article-title":"Role of probiotics in human gut microbiome-associated diseases","volume":"29","author":"Kim","year":"2019","journal-title":"J. Microbiol. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bengoa, A.A., Dardis, C., Garrote, G.L., and Abraham, A.G. (2021). Health-promoting properties of Lacticaseibacillus paracasei: A focus on kefir isolates and exopolysaccharide-producing strains. Foods, 10.","DOI":"10.3390\/foods10102239"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Yang, T., Fan, X., Li, D., Zhao, T., Wu, D., Liu, Z., Long, D., Li, B., and Huang, X. (2023). High Antioxidant Capacity of Lacticaseibacillus paracasei TDM-2 and Pediococcus pentosaceus TCM-3 from Qinghai Tibetan Plateau and Their Function towards Gut Modulation. Foods, 12.","DOI":"10.3390\/foods12091814"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Lin, E.-K., Chang, W.-W., Jhong, J.-H., Tsai, W.-H., Chou, C.-H., and Wang, I.-J. (2023). Lacticaseibacillus paracasei GM-080 ameliorates allergic airway inflammation in children with allergic rhinitis: From an animal model to a double-blind, randomized, placebo-controlled trial. Cells, 12.","DOI":"10.3390\/cells12050768"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Guo, W., Tang, X., Zhang, Q., Xiong, F., Yan, Y., Zhao, J., Mao, B., Zhang, H., and Cui, S. (2024). Lacticaseibacillus paracasei CCFM1222 Ameliorated the Intestinal Barrier and Regulated Gut Microbiota in Mice with Dextran Sulfate Sodium-Induced Colitis. Probiotics Antimicrob. Proteins, 1\u201313.","DOI":"10.1007\/s12602-024-10236-0"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"105150","DOI":"10.1016\/j.jff.2022.105150","article-title":"Lactobacillus paracasei improves dietary fatty liver by reducing insulin resistance and inflammation in obese mice model","volume":"95","author":"Ji","year":"2022","journal-title":"J. Funct. Foods"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/fsn3.1118","article-title":"Lactobacillus paracasei Jlus66 extenuate oxidative stress and inflammation via regulation of intestinal flora in rats with non alcoholic fatty liver disease","volume":"7","author":"Wang","year":"2019","journal-title":"Food Sci. Nutr."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S0006-2952(01)00679-7","article-title":"Effect of metformin on fatty acid and glucose metabolism in freshly isolated hepatocytes and on specific gene expression in cultured hepatocytes","volume":"62","author":"Fulgencio","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11684-015-0384-0","article-title":"Metformin and metabolic diseases: A focus on hepatic aspects","volume":"9","author":"Zheng","year":"2015","journal-title":"Front. Med."},{"key":"ref_33","first-page":"76","article-title":"Non-alcoholic fatty liver disease: Growing burden, adverse outcomes and associations","volume":"8","author":"Kumar","year":"2020","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"154925","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metabolism"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Meroni, M., Longo, M., and Dongiovanni, P. (2019). The role of probiotics in nonalcoholic fatty liver disease: A new insight into therapeutic strategies. Nutrients, 11.","DOI":"10.3390\/nu11112642"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Kim, H., Lee, K., Kim, J.-Y., Shim, J.-J., Lim, J., Kim, J.-Y., and Lee, J.-L. (2023). Lactobacillus helveticus Isolated from Raw Milk Improves Liver Function, Hepatic Steatosis, and Lipid Metabolism in Non-Alcoholic Fatty Liver Disease Mouse Model. Microorganisms, 11.","DOI":"10.3390\/microorganisms11102466"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.2174\/1568026617666161214150959","article-title":"Eradicating bacterial biofilms with natural products and their inspired analogues that operate through unique mechanisms","volume":"17","author":"Garrison","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1042\/BCJ20190500","article-title":"The synthesis of branched-chain fatty acids is limited by enzymatic decarboxylation of ethyl-and methylmalonyl-CoA","volume":"476","author":"Dewulf","year":"2019","journal-title":"Biochem. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1872-034X.2008.00464.x","article-title":"Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease","volume":"39","author":"Mitsuyoshi","year":"2009","journal-title":"Hepatol. Res."},{"key":"ref_40","first-page":"505","article-title":"Expression of fatty acid synthase in nonalcoholic fatty liver disease","volume":"3","author":"Dorn","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1210\/me.2004-0213","article-title":"Hepatic CCAAT\/enhancer binding protein \u03b1 mediates induction of lipogenesis and regulation of glucose homeostasis in leptin-deficient mice","volume":"18","author":"Matsusue","year":"2004","journal-title":"Mol. Endocrinol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.7150\/ijms.27953","article-title":"Phenotypic alteration of hepatocytes in non-alcoholic fatty liver disease","volume":"15","author":"Lakhani","year":"2018","journal-title":"Int. J. Med. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-017-0136-y","article-title":"Differential effects of reticulophagy and mitophagy on nonalcoholic fatty liver disease","volume":"9","author":"Pang","year":"2018","journal-title":"Cell Death Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.5009\/gnl20367","article-title":"Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: Insights from the cellular to patient levels","volume":"15","author":"Pinyopornpanish","year":"2021","journal-title":"Gut Liver"},{"key":"ref_45","first-page":"452","article-title":"Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings","volume":"11","author":"Khosravi","year":"2011","journal-title":"Hepat. Mon."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Ali, A.H., Petroski, G.F., Diaz-Arias, A.A., Al Juboori, A., Wheeler, A.A., Ganga, R.R., Pitt, J.B., Spencer, N.M., Hammoud, G.M., and Rector, R.S. (2021). A model incorporating serum alkaline phosphatase for prediction of liver fibrosis in adults with obesity and nonalcoholic fatty liver disease. J. Clin. Med., 10.","DOI":"10.3390\/jcm10153311"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/kjm2.12395","article-title":"Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study","volume":"37","author":"Chen","year":"2021","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Tu, L.N., Showalter, M.R., Cajka, T., Fan, S., Pillai, V.V., Fiehn, O., and Selvaraj, V. (2017). Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-05040-6"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Lee, J.-H., Lee, H.S., Cho, A.-R., Lee, Y.-J., and Kwon, Y.-J. (2021). Non-alcoholic fatty liver disease is an independent risk factor for LDL cholesterol target level. Int. J. Environ. Res. Public Health, 18.","DOI":"10.3390\/ijerph18073442"},{"key":"ref_50","first-page":"715","article-title":"The product of triglycerides and glucose as biomarker for screening simple steatosis and NASH in asymptomatic women","volume":"15","year":"2017","journal-title":"Ann. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1080\/19490976.2020.1712984","article-title":"Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome","volume":"11","author":"Lee","year":"2020","journal-title":"Gut Microbes"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_53","first-page":"e45884","article-title":"Hepatocytic Ballooning in Non-alcoholic Steatohepatitis: Bridging the Knowledge Gap and Charting Future Avenues","volume":"15","author":"Singla","year":"2023","journal-title":"Cureus"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1586\/egh.11.16","article-title":"Cell death and nonalcoholic steatohepatitis: Where is ballooning relevant?","volume":"5","author":"Machado","year":"2011","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic fatty liver disease and type 2 diabetes mellitus","volume":"22","author":"Dharmalingam","year":"2018","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Vancells Lujan, P., Vinas Esmel, E., and Sacanella Meseguer, E. (2021). Overview of non-alcoholic fatty liver disease (NAFLD) and the role of sugary food consumption and other dietary components in its development. Nutrients, 13.","DOI":"10.3390\/nu13051442"},{"key":"ref_57","first-page":"109","article-title":"Carbohydrate intake and nonalcoholic fatty liver disease: Fructose as a weapon of mass destruction","volume":"4","author":"Basaranoglu","year":"2015","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"687","DOI":"10.3390\/livers3040045","article-title":"Crosstalk between Lipids and Non-Alcoholic Fatty Liver Disease","volume":"3","author":"Gowda","year":"2023","journal-title":"Livers"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/18\/9870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:54:56Z","timestamp":1760111696000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/18\/9870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,12]]},"references-count":58,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["ijms25189870"],"URL":"https:\/\/doi.org\/10.3390\/ijms25189870","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,12]]}}}